Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AUTX-703 |
| Synonyms | |
| Therapy Description |
AUTX-703 is a selective degrader of KAT2A and KAT2B, which potentially induces differentiation and inhibits growth of tumor cells and decreases tumor growth (Eur J Cancer 211S1 (2024): 114620, Blood (2024) 144 (Supplement 1): 3585). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AUTX-703 | AUTX 703|AUTX703 | AUTX-703 is a selective degrader of KAT2A and KAT2B, which potentially induces differentiation and inhibits growth of tumor cells and decreases tumor growth (Eur J Cancer 211S1 (2024): 114620, Blood (2024) 144 (Supplement 1): 3585). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06846606 | Phase I | AUTX-703 | Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Recruiting | USA | 0 |